At what cumulative paclitaxel dose does severe neuropathy typically occur?

Grade 3 neuropathy typically emerges after cumulative doses of 1,000–1,400 mg/m2 with weekly paclitaxel or 6+ cycles of 3-weekly 175 mg/m2. Risk is higher with pre-existing diabetes, prior neurotoxic therapy, and alcohol use.

Is nab-paclitaxel less neurotoxic than solvent-based paclitaxel?

Nab-paclitaxel (Abraxane) causes peripheral neuropathy at similar or higher rates but without Cremophor-related hypersensitivity. Grade 3+ sensory neuropathy occurs in approximately 10% of patients on weekly nab-paclitaxel at 100–125 mg/m2.

Paclitaxel Neuropathy Cumulative Risk

Assess peripheral neuropathy risk from cumulative paclitaxel exposure, with dose modification thresholds: grade 2 neuropathy warrants 20% dose reduction; grade 3 neuropathy requires treatment hold.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.

How It Works

Assess peripheral neuropathy risk from cumulative paclitaxel exposure, with dose modification thresholds: grade 2 neuropathy warrants 20% dose reduction; grade 3 neuropathy requires treatment hold

Each component has a specific meaning:

Cumulative paclitaxel exposure — The cumulative paclitaxel exposure recorded for the scenario being assessed.

Note: Interpret the paclitaxel neuropathy result against the thresholds and context described above.

How to Use

Enter the cumulative paclitaxel exposure for the scenario you are assessing. Assess peripheral neuropathy risk from cumulative paclitaxel exposure, with dose modification thresholds: grade 2 neuropathy warrants 20% dose reduction; grade 3 neuropathy requires treatment hold. Use the paclitaxel neuropathy result to inform your calculation.

Related Calculators

Docetaxel Edema

Medical Long-tail

Vincristine Limit